Company Products Research Collaborators Regulatory Investor Relations Contact Us  

Company

About Us
The formation of Nuovo Biologics represents several years of research and development exploring new broad spectrum antiviral, as well as oncology, technologies. Founded in 2010 and based in Florida, the Company is commercializing an innovative set of protein drugs. Our first drug formulation is "PVX", which appears to treat a broad spectrum of viral infections, including those caused by herpes, influenza, and particular retroviruses; another, "MMX", for specific malignant tumors. Both drugs are expected to be effective across animal species, and possibly, in humans.

Our Philosophy/Mission
Nuovo Biologics is dedicated to the research and development of the most innovative, safe and efficacious drugs and biologicals to best support, and maximize the health and wellness of human and animals. The Company bases its mission and philosophy on the precepts of One Health. We are dedicated to providing information sharing, training and education for clinical research and new product development promoting health, wellness and advocacy among all industry stakeholders.

Our Team

Nuovo Biologics has assembled a core team of key skilled employees disciplined in protein chemistry, molecular biology, virology, clinical study management, pharmaceutical manufacturing, business management and development. It has also brought together a well established and well respected group of academic investigators who are collaborating with Nuovo's scientists.
Board of Directors

Jeffrey Fisher, Chairman

Donald Howard

Dr. Kent Miller

Betty Rich

Dr. Jay Yourist, CEO


Jeff Fisher, RPh
Chairman

Mr. Fisher was formally the EVP of Business Development for Acaria Health, Inc. a position he has held since January 1, 2014 to April 15, 2016. In his current position Mr. Fisher is responsible for oversight of strategic business acquisitions as well as business opportunities with key accounts. Prior to his current position, Mr. Fisher was the COO of Acaria Health a position he held from January 1, 2011 through 8 months post sale to Centene Corporation on April 1, 2013. Previously he was the President and CEO of Fisherx Consulting, LLC from October 1, 2006 to December 31, 2010. In addition, Mr. Fisher was VP of Purchasing and Manufacturer Relations for MedMark, Inc. from October 1, 2003 up until its sale to Walgreens in September 30, 2006.

He was President and CEO of Fisher’s SPS, Inc, positions that he held with that entity since its formation in 1998 up until its sale on October 1, 2003 to MedMark, Inc. Also, from 1991 up until its sale on June 1, 2004 to Care Capital Management, Mr. Fisher was the President and CEO of Fisher’s Pharmacy, an entity which he founded. Mr. Fisher was also a founding member and served on the Board or Directors of Three Rivers Pharmaceuticals, LLC, a privately held pharmaceutical drug manufacturing company, from April of 2000 up until its sale to Kadmon Pharmaceuticals in October 2010. In March of 2006 Mr. Fisher became a principle and board member for Creehan and Co., a nationally based Healthcare IT company. Mr. Fisher was formerly a Pharmacist/Manager with Thrift Drug from 1986 to 1991 and a Pharmacist/Assistant Manager with Thrift Drug from 1985 to 1986. Mr. Fisher received his Bachelor of Science Degree in Pharmacy from Duquesne University in 1985.

In 2006 Mr. Fisher was awarded the prestigious Ernst and Young Entrepreneur of the Year in Health and Life Sciences for Upstate New York and Western Pennsylvania. Mr. Fisher’s other activities included past President of Legend Pharmacies of Western Pennsylvania from 1996 to 1998 and a member of the Board of Directors of the Allegheny County Pharmacists Association. Mr. Fisher currently serves on the Duquesne University School of Pharmacy curriculum and planning board and in 2005 he was awarded the Duquesne University School of Pharmacy Distinguished Alumni Award.


 
Jay Yourist, PhD
President & Chief Executive Officer

Dr. Yourist has held a broad range of management and research positions with both the public and private sectors. He began his career as an Assistant Professor at the University of Miami, School of Medicine, Department of Medicine. His research interests included antiviral properties of natural toxin derivatives and processes mediated by phosphorylation. He was then appointed by the Governor of Florida as Division Director of the State of Florida Division of Vocational Rehabilitation and the Social Security Office of Disability Determination, overseeing more than 2,200 employees and managing an annual budget of almost $290 million for healthcare and community‐based services for disabled adults in the State of Florida. In this position he also managed Florida’s Head Trauma and Spinal Cord Injury Programs including research funding. Subsequently he served as the CEO of Skilled Health Systems (SHS) and Vice President of its sister company, ClinTrials Network. SHS managed outpatient rehabilitation, diabetes and wound care programs. ClinTrials Network was a CRO managing clinical studies in primarily wound care.

For almost fifteen years until 2009, Dr. Yourist served as the Executive Director of the International Institute for Healthcare and Human Development (IIHHD), a 501(c) non‐profit volunteer organization that he co‐founded. Initially funded by Rotary International grants, the IIHHD researched and developed new practices, policies, systems and training programs to improve healthcare delivery and social integration for persons with disabilities primarily in the twenty Caribbean CARICOM nations. During his tenure, he created multiple strategic partnerships, secured funding and directed the development of care reform plans for chronic disease and disability management.

Dr. Yourist is a co‐founder and currently serves as the President and CEO of Nuovo Biologics. He holds full responsibility over the company’s clinical studies, basic research and development operations, information technology implementation, as well as business management from an executive standpoint. He personally manages all intellectual property and FDA regulatory management compliance requirements for claim approval. With his research staff he co‐ authors all publications that result from in‐house research and grant submissions. In this position, he also develops and maintains a broad range of academic and private partnerships and collaborations.



Stuart P. Rose
Vice President for Business Development

Stuart Rose holds a Bachelor’s degree in Business Administration from the University of Miami and has over forty years of involvement in federal, state and local government. After graduation and roles at the Florida Attorney General’s office, and later for Miami-Dade County Mayor Steve Clark, Mr. Rose was a founding partner in Project Masters, a full service Public Relations firm specializing in political campaigns, governmental relations and special event planning. There, he and his partners made a reputation for successfully guiding a series of high profile election victories for local, state and congressional office holders. For nearly two decades, Project Masters provided its clients with campaign victories, project victories and sound advice along the way.

Following his years at Project Masters, Mr. Rose focused on strategic planning and relationship marketing for large companies and organizations. His firm offered its clients access to those “decision makers” who were vital to their projects’ success. From contact to completion, he assisted his clients in navigating the often-complex processes of both government and “Network Marketing.” His decision maker network strategies were proven successful.

Over the years, Mr. Rose has participated in projects and regularly serviced clients with interest in such diverse fields as health care, aviation support services, solid waste, engineering, technology, communications and security, to mention a few. At Nuovo, Mr. Rose will oversee the development of our professional networks and be responsible for the company’s image and branding.



Debbie Somers
Interim COO

Debbie Somers is a Small Business and Health Information Technology (HIT) consultant for academic, commercial and government clients. In her previous position as Senior Advisor to the Deputy Commissioner for Systems, Social Security Administration, Ms. Somers’ vision and energy initiated the SSA HIT program, building the program to national recognition. Ms. Somers devised ways to achieve SSA’s goals while also providing a broader value to the healthcare industry and the community at‐large. Her emphasis on the strategic planning and business impacts for organizations and agencies established a basis for expansion and adoption of national programs. During her tenure she received numerous awards and recognition at the national level from both government and private industry.

As a consultant she has advised organizations on strategic planning for Health IT and disability, and organized think tank sessions to discuss cognitive disabilities. These feats are accomplished by routinely convening diverse organizations and stakeholders to collaborate, identify common goals, and achieve results. Ms. Somers also applies her broad background expertise to partner with small businesses to develop and strengthen their business administration including strategic planning, human resource foundations, information technology oversight and planning, business continuity approaches, and development of policies and procedures to establish a strong security baseline.


Anthony LaVecchia
Director of Operations

Anthony LaVecchia received his Bachelor of Science degree in Chemistry from the Florida International University in Miami. After graduation, he worked for 15 years for Coulter Corporation (Beckman Coulter Inc.) starting as a Chemical Safety Coordinator, then moving through research and development in the Analytical Chemistry and Radio‐Chemistry departments, where he was responsible for radioisotope tagging of the CD20 marker for non‐Hodgkin’s lymphoma and optimizing the analytical release assays for the drug. Anthony was promoted to Senior Scientist in Retrovirology Manufacturing Technical Operations for the FDA Licensed HIV‐1 p24 Antigen Assay, where he worked for the last 10 years of his employment with Beckman Coulter. Anthony then held the position of Supervisor of Analytical Quality Control at Goodwin Biotech, a biologics contract manufacturing organization. Anthony’s responsibilities included overseeing the release of multiple cGMP manufactured vaccines, as well as several oncology products for FDA Phase I, II and III Human Clinical Trials.

Anthony next managed a research and development laboratory as Senior Scientist for a medical diagnostic company, Health Chem Diagnostics LLC. During his four years at Health Chem, Anthony’s work primarily involved improving a transdermal glucose detection meter for diabetics, preparing IRB’s for in house clinical trials, and acting as sub‐ investigator for clinical studies.

At Nuovo Biologics Mr. LaVecchia is responsible for all manufacturing operations including optimizing development processes. He oversees the development of our manufacturing facilities, including building a cGMP compliant facility and sourcing equipment for large‐scale manufacturing purposes. Mr. LaVecchia is also responsible for the completion of the CMC (Chemistry, Manufacturing and Controls) FDA regulatory submission, which includes process validation and implementation for commercial manufacturing.


Patrick Corsino, PhD
Director of Research and Development

Dr. Corsino has several years of research experience in the biomedical sciences. While at the University of Florida, he was involved in research projects ranging from cancer microbiology and therapeutics, to protein structure and chemistry, to antimicrobial agents. This work has been included in 15 peer‐reviewed journals.Dr. Corsino also has had significant industry experience. He has worked as laboratory manager, and has been in charge of quality control/quality assurance at one of the largest compounding pharmacies in the United States.

Since joining Nuovo Biologics, Dr. Corsino has taken over as the Director of Research and Development. He oversees research conducted in‐house, including studies involved in cell culture, protein chemistry, and in vitro assays. He also coordinates the network of collaborators that Nuovo Biologics has access to, directing research involved in virology, immunology and animal studies.

Kent Miller, Ph.D., M.D.

Dr. Miller is Professor Emeritus of Medicine and Microbiology at the University Of Miami School Of Medicine where he served as Chief of Laboratory Medicine and Director of clinical laboratories for the University of Miami Hospitals and Clinics. Previously, Dr. Miller served as the Assistant Director and Chief of Laboratory Medicine for the New York State Department of Health, and Associate Professor of Pathology at Albany Medical College.

Dr. Miller’s research interests are primarily focused on clinical diagnostics and the clinical applications of natural toxins. He performed extensive work on bacterial toxins, especially tetanus toxin, and the development of tetanus toxoid for human use. While at the University of Miami, Dr. Miller collaborated with Dr. Maury Sanders to research the antiviral properties of snake a-toxins. Dr. Miller continued research on PVX (formerly known as PANAVIRA™) and on developing innovative clinical diagnostics. Furthermore, Dr. Miller has authored several papers in peer reviewed journals on this antiviral technology. He has one approved patent and another patent application in review for PVX.

Dr. Miller oversees the management and monitoring of current research processes, the development of the new bioengineered production process, support of the FDA approval process and support of all new patent applications.


Jay E. Yourist, Ph.D.

As a colleague in the Department of Microbiology at the University of Miami, Dr. Yourist worked with Dr. Miller, his Ph.D. advisor, to perform the initial basic research of this technology including its mechanism of action.

As the founder and CEO of CRP Network, LLC in Miami, Florida, he guided an organization that provided clinical research services for new biotechnologies, nutraceuticals and medical devices primarily in the specialty areas of cardiovascular disease, diabetes, infectious disease, rheumatology, wound care, and physical rehabilitation.

Also, Dr. Yourist served as an Assistant Professor of Medicine at the University Of Miami School Of Medicine, where he had both teaching and basic research responsibilities. His research included studies in virology, neurochemistry and enzymology focusing on processes mediated by phosphorylation.

Dr. Yourist has published several papers and has a patent application in current review regarding “Coordinated Healthcare and Disability Management Systems.”

Dr. Yourist will serve as our Chief Executive Officer (See Our Management Team) and in addition to his overall management responsibilities, he will concentrate on the clinical trials, the FDA approval process, and the development of the new synthesis and bioengineered production processes.


Patrick Corsino, Ph.D.

Dr. Patrick Corsino received his Bachelor of Science degree in Medical Biochemistry from the University of Birmingham in the United Kingdom. He then earned his PhD in Pharmacology and Therapeutics from the University of Florida under the guidance of Dr. Brian Law. After graduation he remained at the University for an additional 2 years as a post-doctoral associate with a fellowship grant from the National Institutes of Health. His research during this period was focused primarily on kinases involved in cell cycle regulation, specifically in regards to cancer.

Dr. Corsino then moved to South Florida to work as quality control director and laboratory manager at one of the largest compounding pharmacies in the United States. During this time he oversaw production of a wide variety of pharmaceuticals and their appropriate testing.

Dr. Corsino now works as the R&D Manager at Nuovo Biologics, directing research to elucidate the mechanism of action of the drugs in the current pipeline. He has presented his research at meetings and conferences across the country and has been an author on 13 publications. He holds a US patent for a portion of his research, and is an owner or a co-owner in 3 different companies.


Anthony LaVecchia, B.S.

Anthony LaVecchia received his Bachelor of Science degree in Chemistry from the Florida International University in Miami. After graduation, he worked for 15 years for Coulter Corporation (Beckman Coulter Inc.) starting as a Chemical Safety Coordinator, then moving through research and development in the Analytical Chemistry and Radio-Chemistry departments, where he was responsible for radioisotope tagging of the CD20 marker for non-Hodgkin’s lymphoma and optimizing the analytical release assays for the drug. Anthony was promoted to Senior Scientist in Retrovirology Manufacturing Technical Operations for the FDA Licensed HIV-1 p24 Antigen Assay, where he worked for the last 10 years of his employment with Beckman Coulter.

Anthony moved on to Goodwin Biotech, a biologics contract manufacturing organization, as the Supervisor of Analytical Quality Control. Anthony’s responsibilities included overseeing the release of multiple cGMP manufactured vaccines as well as several oncology products for FDA Phase I, II and III Human Clinical Trials.

Anthony next managed a research and development laboratory as Senior Scientist for a medical diagnostic company, Health Chem Diagnostics LLC. During his four years at Health Chem, Anthony’s work primarily involved improving a transdermal glucose detection meter for diabetics. Other responsibilities included submitting IRB’s for in house clinical trials and acting as sub-investigator for the clinical studies and preparing the device for clinical trials in the European Union. While at Health-Chem, Anthony was responsible for various other medical devices such as lateral flow assays for cholesterol, nitrites in urine and malaria.

In 2012, Anthony started his own consulting firm, APL Scientific Consulting Inc., which enabled him to take a contract position at Nuovo Biologics. Once on board, he realized the potential of the product line at Nuovo and quickly purchased stock in the company, becoming an owner. After starting out in the R & D department, he now is the Director of Operations for Nuovo, implementing FDA regulations that will bring the facility to the cGLP and eventually cGMP status. Some of his responsibilities at Nuovo Biologics include writing CMC for FDA submission, oversight of facility compliance, manufacture of product for use in pilot studies, working with Research and Development to find innovative ways to improve our manufacturing process and pinpoint the mechanism of action for our product.


Ezequiel Martinez, M.S

Shortly after completing a six-year degree program in Biochemistry at the University of Buenos Aires, Ezequiel moved to California and began his scientific career at Amgen. During those eight years in the Pharmaceutical industry, Ezequiel gained valuable experience while working in the Process Development, Research and Development and Preformulation departments at Amgen. The main skills he developed include high throughput drug candidate screening and selection, solid-state characterization, in-vivo study design, and formulation development. Ezequiel then earned his Master’s degree in Biotechnology and Bioinformatics from California State University, Channel Islands and moved to Boise, Idaho to work on a research study funded by the Department of Defense aiming at developing a nanoparticle-based vaccine delivery system against the West Nile Virus. Ezequiel’s research, both at Amgen and at Boise State University, resulted in peer reviewed publications and presentations.

Ezequiel joined Nuovo Biologics’ Research and Development Department in 2013, and is working with Dr. Corsino on the elucidation of the mechanism of action of Nuovo’s therapeutics, as well as on the scale-up and optimization of current processes.


Monica Dors Rodlitz, B.S.

Monica Dors Rodlitz graduated from the University of Washington in Seattle Washington with a BS in Cell and Molecular Biology and Biochemistry. While pursuing her degree, Monica joined then-UW faculty member Dr. Lee Hood’s laboratory mapping and sequencing DNA for the Human Genome Project. In 2000, Monica followed Dr Hood, joining his non-profit Institute for Systems Biology at its inception and working for several years in each of their core facilities: genomics, immunology and proteomics contributing to numerous projects and published papers. Monica brings her 15+ years of biotech experience to the Nuovo team joining Nuovo Biologics at the Davie facility in February 2012. Currently, Monica works as an Associate Scientist in the Research Department.